FRI0035 Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling

Background Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell network profiling (SCNP) is a multiparametric flow cytometry-based assay that measures induced changes (phosphorylation) in intracellul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.393-394
Hauptverfasser: Ptacek, J., Hawtin, R., Louie, B., Evensen, E., Cordeiro, J., Mittleman, B., Atallah, M., Cesano, A., Cavet, G., Bingham, C.O., Cofield, S.S., Curtis, J.R., Danila, M.I., Furie, R., Genovese, M.C., Levesque, M.C., Moreland, L.W., Nigrovic, P.A., O'Dell, J.R., Robinson, W.H., Shadick, N.A., St. Clair, E.W., Striebich, C., Thiele, G.M., Gregersen, P.K., Bridges, S.L.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 394
container_issue Suppl 2
container_start_page 393
container_title Annals of the rheumatic diseases
container_volume 73
creator Ptacek, J.
Hawtin, R.
Louie, B.
Evensen, E.
Cordeiro, J.
Mittleman, B.
Atallah, M.
Cesano, A.
Cavet, G.
Bingham, C.O.
Cofield, S.S.
Curtis, J.R.
Danila, M.I.
Furie, R.
Genovese, M.C.
Levesque, M.C.
Moreland, L.W.
Nigrovic, P.A.
O'Dell, J.R.
Robinson, W.H.
Shadick, N.A.
St. Clair, E.W.
Striebich, C.
Thiele, G.M.
Gregersen, P.K.
Bridges, S.L.
description Background Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell network profiling (SCNP) is a multiparametric flow cytometry-based assay that measures induced changes (phosphorylation) in intracellular signaling proteins, providing a functional measure of pathway activity and immune networking in multiple cell subsets without physical separation. Objectives Induced signaling was measured in specific subsets of monocytes, B and T cells from RA patients (pts) initiating new treatment, and analyzed to build models to predict treatment response. Methods PBMCs from RA pts (n=87) starting TNF inhibitors (TNFi) were examined by SCNP of 42 nodes (combinations of modulator and intracellular readout) within 21 immune cell subsets. A subset of ∼200 RA pts from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository (TETRAD) were studied. Blood samples were collected before treatment with TNFi (adalimumab, etanercept, infliximab, golimumab). Clinical data included DAS28 and EULAR response criteria at baseline, 3, 6, and 12 months. For the 53 evaluable patients, ordinal logistic regression and multivariate modeling were performed to identify signaling profiles associated with response to TNFi. Results Immune cell subsets from RA pts before TNFi treatment exhibited heterogeneity in induced intracellular signaling. Of note, T cell receptor (TCR) and IFNα modulation produced cell subset-specific signaling profiles that were associated with response at 3 months. Specifically, in CD4−CD45RA+ (naive and effector) T cells, phosphorylation of CD3ζ after stimulation through the TCR (TCR→p-CD3ζ) was weakest in pts that had a good EULAR response to TNFi (p=0.04). In contrast, phosphorylation of STAT3 after stimulation with IL-6 (IL-6→p-STAT3) in naive CD4+ T cells was weakest in autoantibody-positive pts with no response (p=0.01). Signaling nodes modulated by IFNα, TNFα, and IL-6 were combined to construct models to predict response and compared to models generated with standard clinical variables, including age, sex, and DAS28. Models utilizing cell signaling capacity of samples had greater performance with an internal cross-validated AUROC of 0.75 compared to 0.45 for clinical models. Figure 1. Range of performance observed over 500 models in bootstrapping. Conclusions This is the first evidence that measurement of peripheral blood immune cell functio
doi_str_mv 10.1136/annrheumdis-2014-eular.2057
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777972390</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008690161</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1270-96eac49cb830240f51216c22b209794f1baa5a9ac0cfc1ac22f9500d98604bd33</originalsourceid><addsrcrecordid>eNqVkc9OGzEQxi1UJNLAO1jivHTs_Wv1hKKmrBSFKISz5fV6icOundpeIW699BF4QZ4EL-mh117GGn_fNzPSD6FrAjeEpMU3YYzbq3FotU8okCxRYy_cDYW8PEMzkhVV_C7gC5oBQJpkrCgv0FfvD7GFilQz9Lbc1lHK33__2TjVahm0Ndh2eLde4trsdaODdXir_NEar7A2eDttFMHqFt-6sHc6aI83ImhlgsePXpsn_BBLr_BC9T1eq_Bi3TPeONvpflLj-NoEJ2SUp4NxPQyjUTH1ZMTkuETnnei9uvr7ztHj8sducZes7n_Wi9tV0hBaQsIKJWTGZFOlQDPockJJISltKLCSZR1phMgFExJkJ4mISsdygJZVBWRNm6ZzdH2ae3T216h84Ac7uniD56QsS1bSlEF0fT-5pLPeO9Xxo9ODcK-cAJ848H848IkD_-TAJw4xXZzSzXD4r-AHxVKWgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777972390</pqid></control><display><type>article</type><title>FRI0035 Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling</title><source>BMJ Journals Online Archive</source><creator>Ptacek, J. ; Hawtin, R. ; Louie, B. ; Evensen, E. ; Cordeiro, J. ; Mittleman, B. ; Atallah, M. ; Cesano, A. ; Cavet, G. ; Bingham, C.O. ; Cofield, S.S. ; Curtis, J.R. ; Danila, M.I. ; Furie, R. ; Genovese, M.C. ; Levesque, M.C. ; Moreland, L.W. ; Nigrovic, P.A. ; O'Dell, J.R. ; Robinson, W.H. ; Shadick, N.A. ; St. Clair, E.W. ; Striebich, C. ; Thiele, G.M. ; Gregersen, P.K. ; Bridges, S.L.</creator><creatorcontrib>Ptacek, J. ; Hawtin, R. ; Louie, B. ; Evensen, E. ; Cordeiro, J. ; Mittleman, B. ; Atallah, M. ; Cesano, A. ; Cavet, G. ; Bingham, C.O. ; Cofield, S.S. ; Curtis, J.R. ; Danila, M.I. ; Furie, R. ; Genovese, M.C. ; Levesque, M.C. ; Moreland, L.W. ; Nigrovic, P.A. ; O'Dell, J.R. ; Robinson, W.H. ; Shadick, N.A. ; St. Clair, E.W. ; Striebich, C. ; Thiele, G.M. ; Gregersen, P.K. ; Bridges, S.L.</creatorcontrib><description>Background Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell network profiling (SCNP) is a multiparametric flow cytometry-based assay that measures induced changes (phosphorylation) in intracellular signaling proteins, providing a functional measure of pathway activity and immune networking in multiple cell subsets without physical separation. Objectives Induced signaling was measured in specific subsets of monocytes, B and T cells from RA patients (pts) initiating new treatment, and analyzed to build models to predict treatment response. Methods PBMCs from RA pts (n=87) starting TNF inhibitors (TNFi) were examined by SCNP of 42 nodes (combinations of modulator and intracellular readout) within 21 immune cell subsets. A subset of ∼200 RA pts from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository (TETRAD) were studied. Blood samples were collected before treatment with TNFi (adalimumab, etanercept, infliximab, golimumab). Clinical data included DAS28 and EULAR response criteria at baseline, 3, 6, and 12 months. For the 53 evaluable patients, ordinal logistic regression and multivariate modeling were performed to identify signaling profiles associated with response to TNFi. Results Immune cell subsets from RA pts before TNFi treatment exhibited heterogeneity in induced intracellular signaling. Of note, T cell receptor (TCR) and IFNα modulation produced cell subset-specific signaling profiles that were associated with response at 3 months. Specifically, in CD4−CD45RA+ (naive and effector) T cells, phosphorylation of CD3ζ after stimulation through the TCR (TCR→p-CD3ζ) was weakest in pts that had a good EULAR response to TNFi (p=0.04). In contrast, phosphorylation of STAT3 after stimulation with IL-6 (IL-6→p-STAT3) in naive CD4+ T cells was weakest in autoantibody-positive pts with no response (p=0.01). Signaling nodes modulated by IFNα, TNFα, and IL-6 were combined to construct models to predict response and compared to models generated with standard clinical variables, including age, sex, and DAS28. Models utilizing cell signaling capacity of samples had greater performance with an internal cross-validated AUROC of 0.75 compared to 0.45 for clinical models. Figure 1. Range of performance observed over 500 models in bootstrapping. Conclusions This is the first evidence that measurement of peripheral blood immune cell function can: 1) identify patients likely to respond to TNFi, and 2) reveal the biology associated with TNFi response or lack thereof. SCNP has revealed predictive biomarkers that, once replicated in future studies, may enable patient stratification in clinical practice and clinical trials. Disclosure of Interest J. Ptacek Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., R. Hawtin Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., B. Louie Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., E. Evensen Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., J. Cordeiro Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., B. Mittleman Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., M. Atallah Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., A. Cesano Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., G. Cavet Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., C. Bingham III: None declared, S. Cofield: None declared, J. Curtis: None declared, M. Danila: None declared, R. Furie: None declared, M. Genovese: None declared, M. Levesque: None declared, L. Moreland: None declared, P. Nigrovic: None declared, J. O'Dell: None declared, W. Robinson: None declared, N. Shadick: None declared, E. W. St. Clair: None declared, C. Striebich: None declared, G. Thiele: None declared, P. Gregersen: None declared, S. L. Bridges, Jr.: None declared DOI 10.1136/annrheumdis-2014-eular.2057</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2014-eular.2057</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.393-394</ispartof><rights>2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/73/Suppl_2/393.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/73/Suppl_2/393.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids></links><search><creatorcontrib>Ptacek, J.</creatorcontrib><creatorcontrib>Hawtin, R.</creatorcontrib><creatorcontrib>Louie, B.</creatorcontrib><creatorcontrib>Evensen, E.</creatorcontrib><creatorcontrib>Cordeiro, J.</creatorcontrib><creatorcontrib>Mittleman, B.</creatorcontrib><creatorcontrib>Atallah, M.</creatorcontrib><creatorcontrib>Cesano, A.</creatorcontrib><creatorcontrib>Cavet, G.</creatorcontrib><creatorcontrib>Bingham, C.O.</creatorcontrib><creatorcontrib>Cofield, S.S.</creatorcontrib><creatorcontrib>Curtis, J.R.</creatorcontrib><creatorcontrib>Danila, M.I.</creatorcontrib><creatorcontrib>Furie, R.</creatorcontrib><creatorcontrib>Genovese, M.C.</creatorcontrib><creatorcontrib>Levesque, M.C.</creatorcontrib><creatorcontrib>Moreland, L.W.</creatorcontrib><creatorcontrib>Nigrovic, P.A.</creatorcontrib><creatorcontrib>O'Dell, J.R.</creatorcontrib><creatorcontrib>Robinson, W.H.</creatorcontrib><creatorcontrib>Shadick, N.A.</creatorcontrib><creatorcontrib>St. Clair, E.W.</creatorcontrib><creatorcontrib>Striebich, C.</creatorcontrib><creatorcontrib>Thiele, G.M.</creatorcontrib><creatorcontrib>Gregersen, P.K.</creatorcontrib><creatorcontrib>Bridges, S.L.</creatorcontrib><title>FRI0035 Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling</title><title>Annals of the rheumatic diseases</title><description>Background Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell network profiling (SCNP) is a multiparametric flow cytometry-based assay that measures induced changes (phosphorylation) in intracellular signaling proteins, providing a functional measure of pathway activity and immune networking in multiple cell subsets without physical separation. Objectives Induced signaling was measured in specific subsets of monocytes, B and T cells from RA patients (pts) initiating new treatment, and analyzed to build models to predict treatment response. Methods PBMCs from RA pts (n=87) starting TNF inhibitors (TNFi) were examined by SCNP of 42 nodes (combinations of modulator and intracellular readout) within 21 immune cell subsets. A subset of ∼200 RA pts from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository (TETRAD) were studied. Blood samples were collected before treatment with TNFi (adalimumab, etanercept, infliximab, golimumab). Clinical data included DAS28 and EULAR response criteria at baseline, 3, 6, and 12 months. For the 53 evaluable patients, ordinal logistic regression and multivariate modeling were performed to identify signaling profiles associated with response to TNFi. Results Immune cell subsets from RA pts before TNFi treatment exhibited heterogeneity in induced intracellular signaling. Of note, T cell receptor (TCR) and IFNα modulation produced cell subset-specific signaling profiles that were associated with response at 3 months. Specifically, in CD4−CD45RA+ (naive and effector) T cells, phosphorylation of CD3ζ after stimulation through the TCR (TCR→p-CD3ζ) was weakest in pts that had a good EULAR response to TNFi (p=0.04). In contrast, phosphorylation of STAT3 after stimulation with IL-6 (IL-6→p-STAT3) in naive CD4+ T cells was weakest in autoantibody-positive pts with no response (p=0.01). Signaling nodes modulated by IFNα, TNFα, and IL-6 were combined to construct models to predict response and compared to models generated with standard clinical variables, including age, sex, and DAS28. Models utilizing cell signaling capacity of samples had greater performance with an internal cross-validated AUROC of 0.75 compared to 0.45 for clinical models. Figure 1. Range of performance observed over 500 models in bootstrapping. Conclusions This is the first evidence that measurement of peripheral blood immune cell function can: 1) identify patients likely to respond to TNFi, and 2) reveal the biology associated with TNFi response or lack thereof. SCNP has revealed predictive biomarkers that, once replicated in future studies, may enable patient stratification in clinical practice and clinical trials. Disclosure of Interest J. Ptacek Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., R. Hawtin Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., B. Louie Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., E. Evensen Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., J. Cordeiro Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., B. Mittleman Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., M. Atallah Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., A. Cesano Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., G. Cavet Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., C. Bingham III: None declared, S. Cofield: None declared, J. Curtis: None declared, M. Danila: None declared, R. Furie: None declared, M. Genovese: None declared, M. Levesque: None declared, L. Moreland: None declared, P. Nigrovic: None declared, J. O'Dell: None declared, W. Robinson: None declared, N. Shadick: None declared, E. W. St. Clair: None declared, C. Striebich: None declared, G. Thiele: None declared, P. Gregersen: None declared, S. L. Bridges, Jr.: None declared DOI 10.1136/annrheumdis-2014-eular.2057</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkc9OGzEQxi1UJNLAO1jivHTs_Wv1hKKmrBSFKISz5fV6icOundpeIW699BF4QZ4EL-mh117GGn_fNzPSD6FrAjeEpMU3YYzbq3FotU8okCxRYy_cDYW8PEMzkhVV_C7gC5oBQJpkrCgv0FfvD7GFilQz9Lbc1lHK33__2TjVahm0Ndh2eLde4trsdaODdXir_NEar7A2eDttFMHqFt-6sHc6aI83ImhlgsePXpsn_BBLr_BC9T1eq_Bi3TPeONvpflLj-NoEJ2SUp4NxPQyjUTH1ZMTkuETnnei9uvr7ztHj8sducZes7n_Wi9tV0hBaQsIKJWTGZFOlQDPockJJISltKLCSZR1phMgFExJkJ4mISsdygJZVBWRNm6ZzdH2ae3T216h84Ac7uniD56QsS1bSlEF0fT-5pLPeO9Xxo9ODcK-cAJ848H848IkD_-TAJw4xXZzSzXD4r-AHxVKWgQ</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Ptacek, J.</creator><creator>Hawtin, R.</creator><creator>Louie, B.</creator><creator>Evensen, E.</creator><creator>Cordeiro, J.</creator><creator>Mittleman, B.</creator><creator>Atallah, M.</creator><creator>Cesano, A.</creator><creator>Cavet, G.</creator><creator>Bingham, C.O.</creator><creator>Cofield, S.S.</creator><creator>Curtis, J.R.</creator><creator>Danila, M.I.</creator><creator>Furie, R.</creator><creator>Genovese, M.C.</creator><creator>Levesque, M.C.</creator><creator>Moreland, L.W.</creator><creator>Nigrovic, P.A.</creator><creator>O'Dell, J.R.</creator><creator>Robinson, W.H.</creator><creator>Shadick, N.A.</creator><creator>St. Clair, E.W.</creator><creator>Striebich, C.</creator><creator>Thiele, G.M.</creator><creator>Gregersen, P.K.</creator><creator>Bridges, S.L.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201406</creationdate><title>FRI0035 Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling</title><author>Ptacek, J. ; Hawtin, R. ; Louie, B. ; Evensen, E. ; Cordeiro, J. ; Mittleman, B. ; Atallah, M. ; Cesano, A. ; Cavet, G. ; Bingham, C.O. ; Cofield, S.S. ; Curtis, J.R. ; Danila, M.I. ; Furie, R. ; Genovese, M.C. ; Levesque, M.C. ; Moreland, L.W. ; Nigrovic, P.A. ; O'Dell, J.R. ; Robinson, W.H. ; Shadick, N.A. ; St. Clair, E.W. ; Striebich, C. ; Thiele, G.M. ; Gregersen, P.K. ; Bridges, S.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1270-96eac49cb830240f51216c22b209794f1baa5a9ac0cfc1ac22f9500d98604bd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ptacek, J.</creatorcontrib><creatorcontrib>Hawtin, R.</creatorcontrib><creatorcontrib>Louie, B.</creatorcontrib><creatorcontrib>Evensen, E.</creatorcontrib><creatorcontrib>Cordeiro, J.</creatorcontrib><creatorcontrib>Mittleman, B.</creatorcontrib><creatorcontrib>Atallah, M.</creatorcontrib><creatorcontrib>Cesano, A.</creatorcontrib><creatorcontrib>Cavet, G.</creatorcontrib><creatorcontrib>Bingham, C.O.</creatorcontrib><creatorcontrib>Cofield, S.S.</creatorcontrib><creatorcontrib>Curtis, J.R.</creatorcontrib><creatorcontrib>Danila, M.I.</creatorcontrib><creatorcontrib>Furie, R.</creatorcontrib><creatorcontrib>Genovese, M.C.</creatorcontrib><creatorcontrib>Levesque, M.C.</creatorcontrib><creatorcontrib>Moreland, L.W.</creatorcontrib><creatorcontrib>Nigrovic, P.A.</creatorcontrib><creatorcontrib>O'Dell, J.R.</creatorcontrib><creatorcontrib>Robinson, W.H.</creatorcontrib><creatorcontrib>Shadick, N.A.</creatorcontrib><creatorcontrib>St. Clair, E.W.</creatorcontrib><creatorcontrib>Striebich, C.</creatorcontrib><creatorcontrib>Thiele, G.M.</creatorcontrib><creatorcontrib>Gregersen, P.K.</creatorcontrib><creatorcontrib>Bridges, S.L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ptacek, J.</au><au>Hawtin, R.</au><au>Louie, B.</au><au>Evensen, E.</au><au>Cordeiro, J.</au><au>Mittleman, B.</au><au>Atallah, M.</au><au>Cesano, A.</au><au>Cavet, G.</au><au>Bingham, C.O.</au><au>Cofield, S.S.</au><au>Curtis, J.R.</au><au>Danila, M.I.</au><au>Furie, R.</au><au>Genovese, M.C.</au><au>Levesque, M.C.</au><au>Moreland, L.W.</au><au>Nigrovic, P.A.</au><au>O'Dell, J.R.</au><au>Robinson, W.H.</au><au>Shadick, N.A.</au><au>St. Clair, E.W.</au><au>Striebich, C.</au><au>Thiele, G.M.</au><au>Gregersen, P.K.</au><au>Bridges, S.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FRI0035 Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2014-06</date><risdate>2014</risdate><volume>73</volume><issue>Suppl 2</issue><spage>393</spage><epage>394</epage><pages>393-394</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell network profiling (SCNP) is a multiparametric flow cytometry-based assay that measures induced changes (phosphorylation) in intracellular signaling proteins, providing a functional measure of pathway activity and immune networking in multiple cell subsets without physical separation. Objectives Induced signaling was measured in specific subsets of monocytes, B and T cells from RA patients (pts) initiating new treatment, and analyzed to build models to predict treatment response. Methods PBMCs from RA pts (n=87) starting TNF inhibitors (TNFi) were examined by SCNP of 42 nodes (combinations of modulator and intracellular readout) within 21 immune cell subsets. A subset of ∼200 RA pts from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository (TETRAD) were studied. Blood samples were collected before treatment with TNFi (adalimumab, etanercept, infliximab, golimumab). Clinical data included DAS28 and EULAR response criteria at baseline, 3, 6, and 12 months. For the 53 evaluable patients, ordinal logistic regression and multivariate modeling were performed to identify signaling profiles associated with response to TNFi. Results Immune cell subsets from RA pts before TNFi treatment exhibited heterogeneity in induced intracellular signaling. Of note, T cell receptor (TCR) and IFNα modulation produced cell subset-specific signaling profiles that were associated with response at 3 months. Specifically, in CD4−CD45RA+ (naive and effector) T cells, phosphorylation of CD3ζ after stimulation through the TCR (TCR→p-CD3ζ) was weakest in pts that had a good EULAR response to TNFi (p=0.04). In contrast, phosphorylation of STAT3 after stimulation with IL-6 (IL-6→p-STAT3) in naive CD4+ T cells was weakest in autoantibody-positive pts with no response (p=0.01). Signaling nodes modulated by IFNα, TNFα, and IL-6 were combined to construct models to predict response and compared to models generated with standard clinical variables, including age, sex, and DAS28. Models utilizing cell signaling capacity of samples had greater performance with an internal cross-validated AUROC of 0.75 compared to 0.45 for clinical models. Figure 1. Range of performance observed over 500 models in bootstrapping. Conclusions This is the first evidence that measurement of peripheral blood immune cell function can: 1) identify patients likely to respond to TNFi, and 2) reveal the biology associated with TNFi response or lack thereof. SCNP has revealed predictive biomarkers that, once replicated in future studies, may enable patient stratification in clinical practice and clinical trials. Disclosure of Interest J. Ptacek Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., R. Hawtin Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., B. Louie Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., E. Evensen Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., J. Cordeiro Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., B. Mittleman Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., M. Atallah Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., A. Cesano Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., G. Cavet Shareholder of: Nodality, Inc., Employee of: Nodality, Inc., C. Bingham III: None declared, S. Cofield: None declared, J. Curtis: None declared, M. Danila: None declared, R. Furie: None declared, M. Genovese: None declared, M. Levesque: None declared, L. Moreland: None declared, P. Nigrovic: None declared, J. O'Dell: None declared, W. Robinson: None declared, N. Shadick: None declared, E. W. St. Clair: None declared, C. Striebich: None declared, G. Thiele: None declared, P. Gregersen: None declared, S. L. Bridges, Jr.: None declared DOI 10.1136/annrheumdis-2014-eular.2057</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2014-eular.2057</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.393-394
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777972390
source BMJ Journals Online Archive
title FRI0035 Prediction of TNF Inhibitor Response in Rheumatoid Arthritis Patients Using Single Cell Network Profiling of Intracellular Immune Signaling
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T16%3A19%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FRI0035%E2%80%85Prediction%20of%20TNF%20Inhibitor%20Response%20in%20Rheumatoid%20Arthritis%20Patients%20Using%20Single%20Cell%20Network%20Profiling%20of%20Intracellular%20Immune%20Signaling&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Ptacek,%20J.&rft.date=2014-06&rft.volume=73&rft.issue=Suppl%202&rft.spage=393&rft.epage=394&rft.pages=393-394&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2014-eular.2057&rft_dat=%3Cproquest_cross%3E4008690161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777972390&rft_id=info:pmid/&rfr_iscdi=true